All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The broad ranges of alcohol and tobacco consumption patterns around the world create significant public health and safety problems. Convincing evidence demonstrated that alcohol and tobacco consumption increases the risk of cancer in the breast, colorectum, liver, esophagus and head and neck \[[@pone.0124045.ref001]--[@pone.0124045.ref003]\]. Cigarette contains amounts of chemicals, including many known carcinogens. The carcinogenic role of cigarette varies depending upon the cigarette product. \[[@pone.0124045.ref004]\]. And the chemical products of alcohol metabolism are also explored to be toxic and hypothesized to cause DNA modifications that lead to cancers \[[@pone.0124045.ref005]\].

Head and neck cancers (HNC) including cancers in the oral cavity, pharynx and larynx, is one of the most common cancer in the world. There are approximately 300,000 oral cancers, 142,000 pharynx cancers and 157,000 larynx cancers been diagnosed each year \[[@pone.0124045.ref006]\]. The theory of multiple factors has been well-investigated. Ecological and individual-based studies have reported higher incidence of HNC in deprived populations \[[@pone.0124045.ref007]\]; lower education and nonprofessional occupations also exhibit a poorer prognosis of HNC \[[@pone.0124045.ref008]\]; in addition, dietary and nutritional habits have been reported to have a relevant role in the development of HNC \[[@pone.0124045.ref009]\]. Most of all, amounts of specific research have reported that alcohol and tobacco consumption are the major lifestyle-related risk factors \[[@pone.0124045.ref002],[@pone.0124045.ref003],[@pone.0124045.ref010]--[@pone.0124045.ref012]\]. However, a great amount of the studies with HNC cancers only focused on the intake of alcohol and tobacco, paying little attention on a precise evidence of an association between different levels of alcohol and tobacco consumption. So it is necessary to explore whether different levels of alcohol and tobacco consumption differ the HNC cancer risk. Therefore, we carried out a meta-analysis of epidemiological published studies to quantify the association between different levels of alcohol and tobacco consumption and patients with head and neck cancer.

Materials and Methods {#sec006}
=====================

Literature search and study inclusion {#sec007}
-------------------------------------

We carried out a systematic literature search in PubMed and ISI Web of Science for articles published before March 2014. We also reviewed references from reviews, meta-analyses and relevant studies for the sake of completeness. The key words used for the literature search was as follows: (alcohol OR alcoholic beverages) AND (smoke OR tobacco consumption) AND (lip cancer OR tongue cancer OR salivary gland cancer OR gingival cancer OR mouth cancer OR pharynx cancer OR larynx cancer). All titles and abstracts were reviewed by two of the authors.

The articles which met the following explicit criteria were included: 1. Case--control or cohort studies; 2. The exposure of interest were alcohol and tobacco consumption; 3. Risk estimates \[odds ratio (OR) or risk ratio (RR)\] and corresponding 95% confidence intervals (CIs) or sufficient data to calculate them were reported; 4. Never and/or occasional (non/occasional) drinking was taken as the reference category; 5. At least three levels of alcohol and tobacco consumption and reporting the OR or RR and 95% CIs or sufficient information to calculate them for each level.

Data extraction {#sec008}
---------------

For each included study, we extracted details on publication year, country, study name, cancer site, study design, variables adjusted or matched, risk estimates and 95% CIs. Two reviewers assessed the quality of included articles, and resolved doubts or disagreements. When same studies were published in more than one paper, only the most recent article was included in the analysis.

Since different studies used different units to measure alcohol consumption, we converted it into a uniform measurement (grams per day (g/day)) and the equivalencies was formulate as 0.8 g/ml = 28g/ounce = 12.5 g/drink. The risk estimates of alcohol consumption were separated into light, moderate, and heavy drinkers, which were ≤12.5 g/day, 12.6--49.9 g/day, and ≥50 g/day of alcohol consumption, respectively \[[@pone.0124045.ref013]\]. Due to the same units of tobacco measurement found in all included studies, we separated tobacco consumption into light, moderate, and heavy smokers, which were ≤19 cigarettes/day, 20--39 cigarettes/day, and ≥40 cigarettes/day of tobacco consumption, respectively. We combined them into a single estimate using the method for pooling non-independent estimates, if more than one value fell into one of these three levels in the study \[[@pone.0124045.ref014]\].

Statistical analysis {#sec009}
--------------------

Because all included publications were case-control studies, we used ORs to measure the interest. When available, we used adjusted risk estimates; otherwise the unadjusted risk estimates were used. Chi-square statistics was calculated to evaluate the heterogeneity across the studies. When P\<0.10, the random effect model was selected, otherwise, the fixed effect model was performed \[[@pone.0124045.ref015]\]. The Egger regression test and Begg-Mazumdar test were used to measure the potential publication bias \[[@pone.0124045.ref016]\]. We carried out meta-regression models to explored potential sources of between-study heterogeneity \[[@pone.0124045.ref017]\]. All statistical analyses were carried out in STATA version 12.0. P \< 0.05 was considered statistically significant. All *P* values were two-sided.

Results {#sec010}
=======

Characteristics of studies {#sec011}
--------------------------

The process of selection of articles for inclusion was summarized in [Fig 1](#pone.0124045.g001){ref-type="fig"}. A total of 2199 relevant articles were identified in initial search, and 28 published studies from 1957 and 2013 were included for this meta-analysis finally. [Table 1](#pone.0124045.t001){ref-type="table"} showed the main characteristics of the 28 studies \[[@pone.0124045.ref018]--[@pone.0124045.ref045]\]. A total of 13830 patients with head and neck cancer were included in the meta-analysis. There were 11 studies conducted in America (6 in the USA), 6 in Asia and 11 in Europe.

10.1371/journal.pone.0124045.t001

###### Characteristics of 28 studies included in the meta-analysis.

![](pone.0124045.t001){#pone.0124045.t001g}

  Study                                                  Country       Cases   Sex                                        Cancer site             Ethnicity   Source of controls   Design
  ------------------------------------------------------ ------------- ------- ------------------------------------------ ----------------------- ----------- -------------------- --------------
  Wynder and Bross \[[@pone.0124045.ref018]\], 1957      USA           297     MF[^a^](#t001fn001){ref-type="table-fn"}   Oral, larynx            Mixed       Population based     Case-control
  Keller and Terris \[[@pone.0124045.ref019]\], 1965     USA           544     MF                                         Oral, larynx            Caucasian   Hospital based       Case-control
  Blot et al. \[[@pone.0124045.ref020]\], 1988           USA           1105    MF                                         Oral, pharynx           Mixed       Population based     Case-control
  Merletti et al. \[[@pone.0124045.ref021]\], 1989       Italy         122     MF                                         Oral, pharynx           Caucasian   Population based     Case-control
  Zheng et al. \[[@pone.0124045.ref022]\], 1990          China         165     M [^b^](#t001fn002){ref-type="table-fn"}   Oral                    Asian       Hospital based       Case-control
  Franceschi et al. \[[@pone.0124045.ref023]\], 1990     Italy         453     MF                                         Oral, larynx, pharynx   Caucasian   Hospital based       Case-control
  Choi and Kahyo \[[@pone.0124045.ref024]\],1991         Korea         364     MF                                         Oral, larynx, pharynx   Asian       Hospital based       Case-control
  Oreggia et al.\[[@pone.0124045.ref025]\], 1991         Uruguay       57      MF                                         Oral                    Caucasian   Hospital based       Case-control
  Maier et al. \[[@pone.0124045.ref026]\], 1994          Germany       106     M                                          pharynx                 Caucasian   Population based     Case-control
  Hayes et al. \[[@pone.0124045.ref027]\], 1999          Puerto Rico   321     MF                                         Oral                    Caucasian   Population based     Case-control
  Bouchardy et al. \[[@pone.0124045.ref028]\], 2000      France        257     MF                                         Oral, larynx, pharynx   Caucasian   Hospital based       Case-control
  Garrote et al. \[[@pone.0124045.ref029]\], 2001        Cuba          160     MF                                         Oral, pharynx           Mixed       Hospital based       Case-control
  Schwartz et al. \[[@pone.0124045.ref030]\], 2001       USA           326     MF                                         Oral                    Mixed       Population based     Case-control
  Zavras et al. \[[@pone.0124045.ref031]\], 2001         Greece        95      MF                                         Oral                    Caucasian   Hospital based       Case-control
  Znaor et al. \[[@pone.0124045.ref032]\],2003           India         2192    M                                          Oral, pharynx           Asian       Hospital based       Case-control
  Castellsague et al. \[[@pone.0124045.ref033]\], 2004   Spain         375     MF                                         Oral, pharynx           Caucasian   Hospital based       Case-control
  Menvielle et al. \[[@pone.0124045.ref034]\], 2004      France        526     MF                                         Larynx, pharynx         Caucasian   Hospital based       Case-control
  Rosenquist et al. \[[@pone.0124045.ref035]\], 2006     Sweden        128     MF                                         Oral, pharynx           Caucasian   Population based     Case-control
  Vlajinac et al. \[[@pone.0124045.ref036]\], 2006       Yugoslavia    100     MF                                         Pharynx                 Caucasian   Population based     Case-control
  Peters et al. \[[@pone.0124045.ref037]\], 2006         USA           692     MF                                         Oral, larynx, pharynx   Mixed       Population based     Case-control
  De Stefani et al. \[[@pone.0124045.ref038]\], 2007     Uruguay       776     MF                                         Oral, pharynx           Caucasian   Hospital based       Case-control
  Applebaum et al. \[[@pone.0124045.ref039]\], 2007      USA           483     MF                                         Oral, larynx, pharynx   Mixed       Hospital based       Case-control
  Subapriya et al. \[[@pone.0124045.ref040]\], 2007      India         388     MF                                         Oral                    Asian       Hospital based       Case-control
  Oze et al. \[[@pone.0124045.ref041]\], 2010            Japan         255     MF                                         Oral, larynx, pharynx   Asian       Hospital based       Case-control
  Boing et al. \[[@pone.0124045.ref042]\], 2011          Brazil        1017    MF                                         Oral, larynx, pharynx   Caucasian   Hospital based       Case-control
  Matsuo et al.\[[@pone.0124045.ref043]\], 2012          Japan         1009    MF                                         Oral, larynx, pharynx   Asian       Hospital based       Case-control
  Radoı et al. \[[@pone.0124045.ref044]\], 2012          France        749     MF                                         Oral                    Caucasian   Hospital based       Case-control
  Bravi et al.\[[@pone.0124045.ref045]\], 2013           Italy         768     MF                                         Oral, pharynx           Caucasian   Hospital based       Case-control

^a^ Male and female

^b^ Male

![Flowchart of selection of studies for inclusion in meta-analysis.](pone.0124045.g001){#pone.0124045.g001}

Meta-analysis {#sec012}
-------------

[Table 2](#pone.0124045.t002){ref-type="table"} showed the major results between different levels of alcohol consumption and HNC cancer risk, including the pooled ORs, 95% CIs and heterogeneity. Moreover, in order to obtain a more precise quantification of the association, stratified analyses by cancer type, regional distribution, and gender were performed. Compared with non/occasional drinkers, the pooled ORs and 95%CIs were 1.29(1.06--1.57), 2.67(2.05--3.48) and 6.63(5.02--8.74) for light drinkers, moderate drinkers and heavy drinkers, respectively in [Fig 2](#pone.0124045.g002){ref-type="fig"}, with significant heterogeneity between study designs (*I* ^*2*^\> 50%). The dose-response analysis was carried out in [Fig 3](#pone.0124045.g003){ref-type="fig"}, and the plot also showed the risk of HNC increased with increasing alcohol consumption. As the gender subgroup analysis showed, there were not significant differences in gender in three different levels. However, patients with pharynx cancers seem more susceptive when alcohol consumption increased. At the same time, no susceptibility of cancer risk was found in larynx cancer patients who drink a little. By Geographic area in classification analysis, the association between alcohol drinking and cancer risk was stronger among people from America and Europe than those from Asia.

10.1371/journal.pone.0124045.t002

###### Odds ratio (95% confidence interval) of pooled and subgroup analysis for head and neck cancers by alcohol intake.

![](pone.0124045.t002){#pone.0124045.t002g}

                        Light vs. non/occasional   Moderate vs. non/occasional   Heavy vs. non/occasional                                                                     
  --------------------- -------------------------- ----------------------------- -------------------------- ------------------- --------- ----- ------------------- --------- -----
  **All studies**       1.29(1.06--1.57)           0.010                         83%                        2.67(2.05--3.48)    \<0.001   92%   6.63(5.02--8.74)    \<0.001   91%
  **Cancer site**                                                                                                                                                             
  Oral                  1.30(1.14--1.49)           \<0.001                       0%                         2.28(1.68--3.10)    \<0.001   87%   3.93(2.78--5.57)    \<0.001   93%
  pharynx               1.39(1.02--1.89)           0.035                         54%                        2.87(1.91--4.30)    \<0.001   73%   5.70(3.61--9.02)    \<0.001   78%
  larynx                0.98(0.75--1.29)           0.880                         0%                         2.06(1.53--2.79)    \<0.001   16%   3.00(1.76--5.11)    \<0.001   64%
  **Gender**                                                                                                                                                                  
  Male                  1.72(1.22--2.44)           0.002                         90%                        3.00(2.29--3.91)    \<0.001   0%    7.46(5.32--10.46)   \<0.001   0%
  Female                1.60(1.04--2.46)           \<0.001                       0%                         5.37(2.22--13.00)   \<0.001   0%    7.84(2.32--26.52)   \<0.001   0%
  **Geographic area**                                                                                                                                                         
  America               1.38(1.06--1.78)           0.020                         76%                        2.98(2.19--4.06)    \<0.001   86%   7.65(5.60--10.45)   \<0.001   81%
  Europe                1.19(0.72--1.98)           0.500                         89%                        2.64(1.35--5.14)    0.004     94%   7.36(3.34--13.24)   \<0.001   95%
  Asia                  1.28(0.91--1.82)           0.160                         82%                        2.22(1.27--3.89)    0.005     95%   4.83(3.15--7.43)    \<0.001   89%

![Forest plots for pooled Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of HNC cancer risks for light, moderate and heavy drinkers.](pone.0124045.g002){#pone.0124045.g002}

![Relative risk function and 95% confidence intervals for the association between alcohol consumption per day and HNC.](pone.0124045.g003){#pone.0124045.g003}

[Table 3](#pone.0124045.t003){ref-type="table"} showed the characteristics of results between different levels of tobacco consumption and HNC cancer risk. Compared with non/occasional smokers, the pooled ORs and 95%CIs were 2.33(1.84--2.95), 4.97(3.67--6.71) and 6.77(4.81--9.53) for light smokers, moderate smokers and heavy smokers in [Fig 4](#pone.0124045.g004){ref-type="fig"}, respectively, with significant heterogeneity between study designs (*I* ^*2*^\> 50%). We also carried out a dose-response analysis in [Fig 5](#pone.0124045.g005){ref-type="fig"}. The result of the plot showed a significantly increased risk of HNC with increasing tobacco consumption. In female patients, no differences were found in light and moderate levels of tobacco intake, but a higher cancer risk was found with heavy tobacco consumption. By cancer type, larynx cancers seem more susceptive when tobacco intake increased. Moreover, patients of HNC in Europe countries were more susceptive in all three different levels. Tobacco consumption was found to be a stronger risk factor for head and neck cancer than alcohol consumption.

10.1371/journal.pone.0124045.t003

###### Odds ratio (95% confidence interval) of pooled and subgroup analysis for head and neck cancers by tobacco intake.

![](pone.0124045.t003){#pone.0124045.t003g}

                        Light vs. non/occasional   Moderate vs. non/occasional   Heavy vs. non/occasional                                                                      
  --------------------- -------------------------- ----------------------------- -------------------------- ------------------- --------- ----- -------------------- --------- -----
  **All studies**       2.33(1.84--2.95)           \<0.001                       88%                        4.97(3.67--6.71)    \<0.001   94%   6.77(4.81--9.53)     \<0.001   94%
  **Cancer site**                                                                                                                                                              
  Oral                  1.51(1.19--1.93)           0.001                         84%                        2.79(1.93--4.04)    \<0.001   91%   4.00(2.57--6.22)     \<0.001   92%
  pharynx               2.07(1.28--3.34)           0.003                         74%                        3.52(2.03--6.11)    \<0.001   78%   5.72(3.34--9.80)     \<0.001   73%
  larynx                2.89(1.81--4.61)           \<0.001                       0%                         5.37(3.33--8.67)    \<0.001   0%    11.30(6.26--20.39)   \<0.001   0%
  **Gender**                                                                                                                                                                   
  Male                  1.68(1.19--2.38)           \<0.001                       32%                        3.25(1.94--5.44)    \<0.001   88%   4.03(2.45--6.62)     \<0.001   41%
  Female                1.62(0.69--3.78)           0.267                         62%                        3.66(2.45--5.48)    \<0.001   0%    7.80(3.04--19.96)    \<0.001   17%
  **Geographic area**                                                                                                                                                          
  America               2.44(1.66--3.58)           \<0.001                       85%                        5.78(3.50--9.53)    \<0.001   92%   6.99(4.72--10.33)    \<0.001   86%
  Europe                2.74(1.53--4.92)           \<0.001                       91%                        7.20(3.37--15.37)   \<0.001   94%   10.48(4.89--22.49)   \<0.001   94%
  Asia                  1.78(1.27--2.50)           \<0.001                       87%                        2.67(2.03--3.52)    \<0.001   80%   3.29(2.64--4.10)     \<0.001   58%

![Forest plots for pooled Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of HNC cancer risks for light, moderate and heavy smokers.](pone.0124045.g004){#pone.0124045.g004}

![Relative risk function and the 95% confidence intervals for the association between tobacco consumption per day and HNC.](pone.0124045.g005){#pone.0124045.g005}

For the head and neck cancer is a chronic process, the duration of alcohol and tobacco consumption should be considered for a risk factor. So we showed results of pooled and subgroup analysis for head and neck cancers by years of cigarette smoking. As shown in [Table 4](#pone.0124045.t004){ref-type="table"}, the pooled ORs and 95%CIs were 1.93(1.37--2.73), 3.39(2.47--4.66) and 3.39(2.47--4.66) for patients who smoke for 1--19 years, 20--40 years and\>40 years, respectively. Unfortunately, we could not get enough data of the duration of alcohol consumption.

10.1371/journal.pone.0124045.t004

###### Odds ratio (95% confidence interval) of pooled and subgroup analysis for head and neck cancers by years of cigarette smoking.

![](pone.0124045.t004){#pone.0124045.t004g}

                        1--19 years        20--39 years   \>40 years                                                                    
  --------------------- ------------------ -------------- ------------ ------------------ --------- ----- ------------------- --------- -----
  **All studies**       1.93(1.37--2.73)   \<0.001        82%          3.39(2.47--4.66)   \<0.001   78%   5.17(3.93--6.80)    \<0.001   70%
  **Cancer site**                                                                                                                       
  Oral                  1.77(1.21--2.61)   0.004          46%          3.33(2.07--5.37)   \<0.001   68%   4.73(1.70--8.29)    \<0.001   76%
  pharynx               2.09(1.08--4.05)   0.029          69%          3.29(1.18--9.13)   0.022     86%   6.03(2.34--15.54)   \<0.001   83%
  larynx                3.18(1.70--5.97)   \<0.001        0%           4.13(2.25--7.58)   \<0.001   0%    9.32(4.06--21.42)   \<0.001   50%
  **Gender**                                                                                                                            
  Male                  1.57(0.86--2.56)   0.138          75%          3.34(1.73--6.43)   \<0.001   77%   4.94(2.84--8.61)    \<0.001   69%
  Female                1.79(0.99--3.27)   0.056          46%          3.26(2.21--4.80)   \<0.001   0%    4.35(2.88--6.59)    \<0.001   0%
  **Geographic area**                                                                                                                   
  America               1.75(0.99--3.11)   0.055          91%          3.35(2.10--5.34)   \<0.001   86%   5.54(3.96--7.74)    \<0.001   73%
  Europe                2.86(1.81--4.52)   \<0.001        27%          4.91(2.56--9.41)   \<0.001   64%   7.46(4.18--13.29)   \<0.001   52%
  Asia                  1.52(1.12--2.06)   0.008          0%           2.14(1.53--3.01)   \<0.001   0%    2.80(2.00--3.92)    \<0.001   0%

Sensitivity analysis and publication bias {#sec013}
-----------------------------------------

In order to compare the difference and evaluate the sensitivity of the meta-analyses, we repeated the meta- analysis with one study excluded at each time. The results did not have significant change of the pooled OR even if the most influential study was omitted. We also excluded studies by different subgroup (cancer site, geographic area, sample size and study time), and we did not find any significant change of the pooled OR (data not shown). These indicated the robustness of our findings. Funnel plot and Egger's test were performed to assess the publication bias. The shape of the funnel plot ([S1](#pone.0124045.s001){ref-type="supplementary-material"}--[S6](#pone.0124045.s006){ref-type="supplementary-material"} Figs) did not show any obvious evidence of asymmetry for *P* = 0.070, *P* = 0.154, *P* = 0.960, *P* = 0.899, *P* = 0.274, and *P* = 0.139, respectively.

Discussion {#sec014}
==========

The results of the present meta-analysis, based on 13,830 HNC cases, provide quantitative testimony for a positive association between alcohol and tobacco consumption and HNC risks. Compared with non/occasional drinkers, we found that alcohol consumption was associated with a significantly increased risk at moderate and heavy levels for HNC patients, while our results showed much higher ORs of pharynx cancer compared with those presented among patients with oral and larynx cancers. Moreover, our results were rather similar to those shown in previous studies \[[@pone.0124045.ref046], [@pone.0124045.ref047]\]. The association between alcohol consumption and cancer risk was stronger among people from America and Europe than those from Asia. One possible theory was that the proportion of moderate and heavy drinkers was higher in America and Europe population. Another possible theory was that people from America and Europe carried a higher prevalence of the polymorphisms of alcohol metabolism related genes, such as aldehyde dehydrogenase (ALDH) and alcohol dehydrogenase (ADH), having a lower risk of some alcohol-related cancer consequently \[[@pone.0124045.ref048],[@pone.0124045.ref049]\].

A significantly increased risk at all three different levels was found from the results of the tobacco consumption meta-analysis. It showed a significantly higher increased risk for larynx cancers than oral and pharynx cancer. One of the possible theory was that fibers of tobacco could be released and then penetrated into the laryngeal tissue, thus becoming a further risk factor initiating tumorigenesis \[[@pone.0124045.ref050]\]. Another possible reason was that the number of studies from larynx is limited. Meanwhile, patients with tobacco smoking habit in Europe countries seemed more susceptive with HNC risks.

In some epidemiologic studies, ethanol had been described as a risk enhancer in smokers, but not as an independent risk factor \[[@pone.0124045.ref051]\]. However, most of the studies provided strong evidence that alcohol consumption, independently from exposure to tobacco consumption, increased the risk of head and neck cancer \[[@pone.0124045.ref020],[@pone.0124045.ref046],[@pone.0124045.ref052],[@pone.0124045.ref053]\]. Unfortunately, we did not get enough data between alcohol and tobacco consumption in patients with HNC, the analysis of the alcohol and tobacco interaction was not explored.

Limitations of our meta-analysis include some possible residual confounding, such as diet, physical activity and human papillomavirus (HPV) infection. But we could not ignore and exclude these residual confounding. Some studies demonstrated that HPV infection is a risk factor for HNC cancer, especially for cancers of the tongue \[[@pone.0124045.ref054],[@pone.0124045.ref055]\]. However, from the result of other different studies, whether the associations between alcohol and tobacco consumption and HNC cancer risk differ according to HPV status was not clear \[[@pone.0124045.ref039],[@pone.0124045.ref056],[@pone.0124045.ref057]\]. Nevertheless, significant heterogeneity among 28 included studies was observed, which possibly due to the study design and quality. However, random-effects model was allowed to be used into compute the heterogeneity \[[@pone.0124045.ref017]\]. Additionally, the lifetime of patients' exposure to alcohol or tobacco and the different type of alcoholic and smoking beverage were not studied in this meta-analysis. Recall bias was another possible limitation of our study, we paid attention to collect the value of alcohol and tobacco consumption in a standardized manner, but differential reporting between articles could not be excluded.

In conclusion, tobacco consumption was found to be a stronger risk factor for head and neck cancer than alcohol consumption. The pharynx was the most affected by the harmful effects of alcohol, while larynx was the most affected by the harmful effects of tobacco. Europeans should pay more attention to harmful effects of tobacco. Tobacco consumption increased the risk of head and neck cancer even for smaller quantities whereas alcohol drinking increased this risk significantly at moderate and heavy levels. Precancerous lesions or cancer at an early stage should be detected by regular check-ups. Prevention efforts should be focused on smoking and drinking cessation \[[@pone.0124045.ref058]\].
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